Evidence map›Paper›PMID 40119744›Full record

ArticleGenes, chromosomes & cancer2025

Germline Whole-Exome Sequencing in Non-Smoker Lung Cancer Patients Reveals Pathogenic Variants in Lung Cancer Driver Genes.

Giovanni Carapezza, Simone Paolo Minardi, Sara Noci, Giulia Pintarelli, Susanna Zanutto, Matteo Incarbone, Davide Tosi, Tommaso Antonio Dragani, Francesca Colombo, Marco Alessandro Pierotti and 1 more

Abstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giovanni CarapezzaCogentech S.R.L.Benefit C. With Only Stakeholder Fondazione IFOM ETS, Milano, Italy.
Simone Paolo MinardiCogentech S.R.L.Benefit C. With Only Stakeholder Fondazione IFOM ETS, Milano, Italy.ORCID 0000-0001-7303-3821
Sara NociFondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Giulia PintarelliFondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Susanna ZanuttoFondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Matteo IncarboneOspedale San Giuseppe, IRCCS Multimedica, Milano, Italy.
Davide TosiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Tommaso Antonio DraganiFondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Francesca ColomboNational Research Council, Institute for Biomedical Technologies, Segrate, Italy.
Marco Alessandro PierottiCogentech S.R.L.Benefit C. With Only Stakeholder Fondazione IFOM ETS, Milano, Italy.
Manuela GariboldiFondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.ORCID 0000-0001-8406-165X

Funding

Associazione Italiana Ricerca sul Cancro AIRC 2017 IG 20226Ministry of Health "Ricerca Corrente"
6 · The paper itself

Abstract

Approximately 10%-15% of all lung cancers arise in non-smokers. Although there are no established aetiological factors, non-smokers with a family history of cancer have an increased risk of lung cancer, implying host genetic factors in lung cancer susceptibility. We sought to identify, in a cohort of 75 patients recruited before lung lobectomy, germline alterations with a strong association with lung cancer. Whole-exome sequencing was performed on genomic DNA from peripheral blood. Six resources were used to select pathogenic germline variants with strong clinical significance. In total, 33 pathogenic or likely pathogenic variants in 31 genes were identified. Of these, 13 were located in cancer-predisposing genes (nine were lung cancer drivers), most of which were involved in DNA repair mechanisms and diseases of metabolism. Among DNA repair-related genes, BRCA1 and BRCA2, and ATM have also been identified in other studies on non-smokers. Our results strongly support the hypothesis that a number of non-smoker lung cancer patients carry germline variants in cancer-predisposing genes, suggesting that lung cancer patients, particularly non-smokers, should be considered for germline molecular testing.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNon-SmokersAdultAgedExome SequencingFemaleGerm-Line MutationHumansMaleMiddle AgedDNA repair‐related genesgenetic risk factorsgermline molecular testingnon‐smoker lung cancerpathogenic germline variants

Identifiers

PMID40119744
PMCPMC11929153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.